CABALETTA BIO, INC. Accretion Expense
CABALETTA BIO, INC. (CABA) reported Accretion Expense of $177.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2026-08-13
- CABALETTA BIO, INC. accretion expense for the quarter ending 2026-06-30 was $96.00K, a 32.39% decline year-over-year.
- CABALETTA BIO, INC. accretion expense for the quarter ending 2026-03-31 was $81.00K, a 51.50% decline year-over-year.
- CABALETTA BIO, INC. accretion expense for the quarter ending 2025-12-31 was $106.00K.
- CABALETTA BIO, INC. accretion expense for the quarter ending 2025-09-30 was $117.00K, a 65.49% decline year-over-year.
- CABALETTA BIO, INC. accretion expense for fiscal 2025 was $532.00K, a 31.36% increase from fiscal 2024.
- CABALETTA BIO, INC. accretion expense for fiscal 2024 was $405.00K, a 0.74% decline from fiscal 2023.
- CABALETTA BIO, INC. accretion expense for fiscal 2023 was $408.00K, a 40.44% decline from fiscal 2022.
- CABALETTA BIO, INC. accretion expense for fiscal 2022 was $685.00K.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $96.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $177.00K 10-Q · filed 2026-08-13 | $283.00K derived: sum of 3 quarters · filed 2026-08-13 | $400.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $81.00K 10-Q · filed 2026-05-14 | $187.00K derived: sum of 2 quarters · filed 2026-05-14 | $304.00K derived: sum of 3 quarters · filed 2026-05-14 | $446.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $223.00K derived: sum of 2 quarters · filed 2026-03-23 | $365.00K derived: sum of 3 quarters · filed 2026-08-13 | $532.00K 10-K · filed 2026-03-23 |
| 2025-09-30 | $117.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $259.00K derived: sum of 2 quarters · filed 2026-08-13 | $426.00K 10-Q · filed 2025-11-10 | $99.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $142.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $309.00K 10-Q · filed 2026-08-13 | -$18.00K derived: sum of 3 quarters · filed 2026-08-13 | $321.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $167.00K 10-Q · filed 2026-05-14 | -$160.00K derived: sum of 2 quarters · filed 2026-05-14 | $179.00K derived: sum of 3 quarters · filed 2026-05-14 | $378.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$327.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $12.00K derived: sum of 2 quarters · filed 2026-03-23 | $211.00K derived: sum of 3 quarters · filed 2026-03-23 | $405.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $339.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $538.00K derived: sum of 2 quarters · filed 2025-11-10 | $732.00K 10-Q · filed 2025-11-10 | $852.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $199.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $393.00K 10-Q · filed 2025-08-07 | $513.00K derived: sum of 3 quarters · filed 2025-08-07 | $603.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $194.00K 10-Q · filed 2025-05-15 | $314.00K derived: sum of 2 quarters · filed 2025-05-15 | $404.00K derived: sum of 3 quarters · filed 2025-05-15 | $498.00K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $120.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $210.00K derived: sum of 2 quarters · filed 2025-03-31 | $304.00K derived: sum of 3 quarters · filed 2025-03-31 | $408.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $90.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $184.00K derived: sum of 2 quarters · filed 2024-11-14 | $288.00K 10-Q · filed 2024-11-14 | $973.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $94.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $198.00K 10-Q · filed 2024-08-08 | $883.00K derived: sum of 3 quarters · filed 2024-08-08 | $883.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $104.00K 10-Q · filed 2024-05-15 | $789.00K derived: sum of 2 quarters · filed 2024-05-15 | $789.00K derived: sum of 3 quarters · filed 2024-05-15 | $789.00K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $685.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $685.00K derived: sum of 2 quarters · filed 2024-03-21 | $685.00K derived: sum of 3 quarters · filed 2024-03-21 | $685.00K 10-K · filed 2024-03-21 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |